Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors
- PMID: 2317810
Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors
Abstract
This study shows that it is not possible to cause regression of the immunogenic SA-1 sarcoma by adoptive immunotherapy with tumor-sensitized T-cells, unless the tumor-bearing recipient is exposed to a sublethal dose of gamma-irradiation to remove a barrier that prevents adoptive immunity from being expressed. This barrier to adoptive immunotherapy was found to be regenerated between 2 and 4 weeks following irradiation, and its regeneration was associated with general repopulation of host T-cells. However, it was not regenerated in the absence of the thymus, thus showing that it is T-cell dependent. Evidence that it is caused by the presence of CD4+ suppressor T-cells was shown by the finding that it can be removed by depleting mice of CD4+ T-cells with anti-L3T4 monoclonal antibodies, but not by depleting them of CD8+ T-cells with anti-Lyt-2 monoclonal antibodies. Again, the barrier could be restored to irradiated recipients by infusing them with CD4+ T-cells, but not with CD8+ T-cells, from tumor-bearing donors. The barrier to adoptive immunotherapy was found to be tumor induced and to be paradoxically generated in concert with host concomitant immunity.
Similar articles
-
Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.J Immunol. 1988 Aug 1;141(3):1047-53. J Immunol. 1988. PMID: 3260908
-
Adoptive immunotherapy of newly induced murine sarcomas.Cancer Res. 1985 Apr;45(4):1657-62. Cancer Res. 1985. PMID: 3872168
-
Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.Lab Invest. 1985 Mar;52(3):304-13. Lab Invest. 1985. PMID: 3974201
-
Adoptive immunotherapy of cancer with immune and activated lymphocytes: experimental and clinical studies.Ric Clin Lab. 1986 Jan-Mar;16(1):1-20. doi: 10.1007/BF02886719. Ric Clin Lab. 1986. PMID: 2874605 Review.
-
The immunological network at the site of tumor rejection.Biochim Biophys Acta. 1986 Aug 5;865(1):1-11. doi: 10.1016/0304-419x(86)90009-0. Biochim Biophys Acta. 1986. PMID: 2942190 Review.
Cited by
-
Immunotherapy of a murine T cell lymphoma localized to the brain.J Neurooncol. 2000 Mar;47(1):1-10. doi: 10.1023/a:1006475516746. J Neurooncol. 2000. PMID: 10930094
-
Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope.Cancer Immunol Immunother. 2010 May;59(5):747-57. doi: 10.1007/s00262-009-0795-3. Cancer Immunol Immunother. 2010. PMID: 19936747 Free PMC article.
-
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street.J Immunol. 2015 Aug 1;195(3):755-61. doi: 10.4049/jimmunol.1500751. J Immunol. 2015. PMID: 26188068 Free PMC article. Review.
-
Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice.J Immunother. 2013 Feb;36(2):124-32. doi: 10.1097/CJI.0b013e31828298e6. J Immunother. 2013. PMID: 23377667 Free PMC article.
-
CD25+ CD4+ regulatory T-cells in cancer.Immunol Res. 2005;32(1-3):155-68. doi: 10.1385/IR:32:1-3:155. Immunol Res. 2005. PMID: 16106066 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Research Materials